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Emergent properties of the interferon-signalling
network may underlie the success of hepatitis C
treatment
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Current interferon alpha-based treatment of hepatitis C virus (HCV) infection fails to cure a
sizeable fraction of patients treated. The cause of this treatment failure remains unknown.
Here using mathematical modelling, we predict treatment failure to be a consequence of the
emergent properties of the interferon-signalling network. HCV induces bistability in the
network, creating a new steady state where it can persist. Cells that admit the new steady
state alone are refractory to interferon. Using a model of viral kinetics, we show that when the
fraction of cells refractory to interferon in a patient exceeds a critical value, treatment fails.
Direct-acting antivirals that suppress HCV replication can eliminate the new steady state,
restoring interferon sensitivity and improving treatment response. Our study thus presents a
new conceptual basis of HCV persistence and treatment response, elucidates the origin of the
synergy between interferon and direct-acting antivirals, and facilitates rational treatment
optimization.
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H
epatitis C virus (HCV) infection is spread over 130–170
million people worldwide1. Pegylated interferon-a (IFN-
a), in combination with ribavirin, forms the mainstay of
the current treatment for HCV infection. The combination (PR),
however, elicits a sustained virological response (SVR) in only
about 50% of HCV genotype 1 infected patients treated2. Several
factors that correlate with treatment response have been
identified, including HCV genotype, pre-treatment viral load
and single-nucleotide polymorphisms (SNPs) in the IFN-l
locus3,4. The cause of treatment failure, however, remains
poorly established.
IFN-a belongs to a family of cytokines produced endogenously
in response to viral infection5,6. Through a complex series of
signalling events involving the JAK–STAT pathway, stimulation
by IFN results in the expression of several hundred IFN-
stimulated genes (ISGs) which together induce an antiviral state
in cells and control infection6. With HCV, however, a vast
majority (B70–80%) of infected individuals are unable to clear
the infection spontaneously and become chronically infected6,7.
PR treatment can compensate for suboptimal immune control of
infection. ISG expression following the onset of treatment was
enhanced substantially over the pre-treatment level in the livers of
HCV patients who responded to PR8–10. (Ribavirin alone elicits
no SVR11, but improves response in combination with IFN12,
suggesting that ribavirin potentiates the anti-HCV activity of
IFN10,13–15.) Surprisingly, however, in the livers of nonres-
ponders to PR treatment, pre-treatment ISG expression was
higher than in responders and did not increase significantly
following the onset of treatment8–10.
Non-responsiveness to PR was eliminated in part by the
recently approved direct-acting antiviral agents (DAAs) telaprevir
and boceprevir, each of which in conjunction with PR yielded
SVR rates of over 70% in previously untreated HCV genotype 1
infected patients2,16. Because telaprevir and boceprevir
monotherapy fail owing to the emergence of drug resistance,
one hypothesis for the success of the triple combination is that
DAAs act on drug sensitive strains whereas PR control resistant
strains17. Paradoxically, however, although the DAAs alone
elicited no SVR, the triple combination induced SVR in 40% of
previous null responders to PR, who showed no significant
decline in viral levels during PR treatment indicating the near
absence of IFN activity18,19. DAAs thus appear to synergize with
IFN and help overcome non-responsiveness to PR.
In two recent pioneering studies, poor response following high-
pre-treatment ISG expression has been suggested to arise from
upregulation, associated with persistent IFN signalling, of
immunosuppressive molecules such as interleukin-10 and
programmed death-ligand 1 (PD-L1), which leads to T-cell
exhaustion and viral persistence20,21. These studies mark a
breakthrough in our understanding of chronic viral infections
and recommend, counter intuitively, suppression of IFN
signalling to avert T-cell exhaustion and elicit control of
chronic infection. Two key questions, however, remain
unanswered. When does HCV infection lead to high (pre-
treatment) ISG expression and therefore poor-treatment
response? How, despite high-exogenous IFN addition, which
would ensure continued immunosuppression following the onset
of treatment, do DAAs improve treatment response in
combination with PR? Mechanisms in addition to IFN-
associated immunosuppression thus appear to contribute to
HCV persistence and treatment response.
Previous studies have identified several mechanisms by which
HCV evades IFN activity: HCV can suppress endogenous IFN
production, inhibit ISG expression by interfering with the
JAK–STAT pathway, induce a block in the translation of ISG
mRNA, and/or inhibit ISG effector functions6,22. At the same
time, key ISGs involved in the control of HCV have been
identified and in some cases their mode of action elucidated23–27.
These specific interactions between HCV and components of the
IFN network have unravelled the many fronts of the battle
between HCV and our innate immune system. The outcome of
this battle, however, has been difficult to predict: the specific
interactions prove inadequate for distinguishing between
nonresponders and responders to PR or explaining the
observed synergy between DAAs and PR, precluding rational
strategies for improving treatment response.
In the present study, we explore the possibility that respon-
siveness to IFN is not a consequence of specific molecular
interactions between individual components of the IFN system
and HCV alone, but of emergent, systems-level properties of the
IFN signalling network interacting with HCV. The IFN network
is designed to suppress HCV upon stimulation. HCV, on the
other hand, interferes with IFN signalling and compromises its
effector functions. Non-responsiveness to IFN may thus be a
manifestation of the state to which the IFN system is driven as a
consequence of these competing interactions. Further, although
DAAs directly target viral (or host) proteins, their action may, at
the systems level, weaken the influence of HCV on the IFN
network and drive the system to an alternative, responsive state.
To test this hypothesis, we construct a mathematical model of the
IFN signalling network in the presence of HCV and elucidate its
systems-level properties. We find intriguingly that HCV induces
bistability in the network, causing the emergence of a new steady
state where HCV persists. Accounting for this bistability, we
develop a mathematical model of viral kinetics and deduce a
criterion for treatment response. Finally, we find that DAAs can
eliminate this bistability and improve treatment response.
Results
Model of the IFN signalling network in the presence of HCV.
We considered the intracellular IFN signalling network in the
presence of HCV (Fig. 1). Upon infection, HCV replicates inside
the cell producing copies of positive and negative strands of RNA,
the latter presumably existing as double-stranded RNA (dsRNA).
In the presence of IFN, ISGs are transcribed to produce ISG
mRNA. The translation of ISG mRNA yields ISG proteins, which
control HCV by inhibiting different steps of the HCV life cycle
and/or lowering the stability of HCV RNA23–27. Of the ninety
ISGs expressed in response to IFN (type I) stimulation, seven
were recently found to exhibit significant activity against HCV24.
HCV can evade IFN action by several mechanisms including
lowering global translation in the cell via protein kinase R
(PKR)28. The latter mechanism has been shown in recent in vitro
studies to facilitate HCV persistence despite strong IFN
treatment28, postulated to be the predominant mode of the
interference of IFN signalling by HCV in vivo29, and may
represent a key pathway underlying the resistance of HCV to
IFN30. We therefore focused here on the HCV-mediated block in
the translation of ISG mRNA via PKR. (We also considered other
mechanisms of the interference of IFN signalling by HCV and
found similar results; see Discussion.) Initiation of translation
depends on the abundance of the eIF2a–guanosine triphosphate
(GTP) complex. eIF2a–GTP gets hydrolyzed to eIF2a–guanosine
diphosphate (GDP) during translation31. The recycling of eIF2a–
GDP to eIF2a–GTP is mediated by another protein eIF2B32.
HCV induces PKR dimerization, presumably by the binding of
HCV double-stranded RNA to PKR33,34. PKR dimers undergo
autophosphorylation34. Phosphorylated PKR catalyzes the
phosphorylation of eIF2a–GDP. Phosphorylated eIF2a–GDP
does not undergo GDP to GTP exchange and has an increased
affinity for eIF2B31,32. eIF2B is present in low abundance
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compared with eIF2a31. Thus, phosphorylated eIF2a–GDP
sequesters eIF2B, which further reduces the eIF2a–GTP level,
blocking translation. HCV, however, continues to replicate as its
translation is less sensitive to eIF2a–GTP28,35–37. The HCV–PKR
interaction thus contains key elements of the suppression of IFN
activity by HCV as well as the control of HCV by IFN, capturing
the essence of the battle between HCV and IFN at the systems
level. We modelled the network using a system of coupled
differential equations (Supplementary Note 1) and elucidated its
emergent properties.
Bistability in the IFN signalling network induced by HCV. The
network exhibits double-negative feedback: ISG proteins control
HCV, whereas HCV controls ISG mRNA translation. Double-
negative feedback with ultra-sensitivity (nonlinearity) can give
rise to bistability38, observed in several signalling and
transcription networks38–42. To test the existence of bistability,
we identified the steady states of the network as follows. We
predicted first the dependence of the steady state ISG protein level
on the HCV RNA level (red line in Fig. 2). Here the double-
stranded HCV RNA level was fixed, thus eliminating the negative
feedback of ISG on HCV, and the system solved for steady state.
This process was repeated for different values of the double-
stranded HCV RNA level. Similarly, we predicted the dependence
of the steady state HCV RNA level on the ISG protein level (blue
line in Fig. 2), by suppressing the negative feedback of HCV on
ISG. When both the feedback loops are active, the intersection
points Q1, Q2 and Q3 represent the steady states of the system
(Fig. 2). At Q1, the HCV RNA level is high and the ISG protein
level low, marking HCV persistence, whereas at Q3, HCV RNA is
absent and the ISG protein level is high, indicating HCV
clearance. Q1 and Q3 are the two stable steady states of the
system. Q2, where HCV RNA and ISG protein levels are
intermediate, is an unstable steady state, in that small
perturbations get amplified and drive the system away from Q2.
Q2, thus acts as a threshold determining which of the two stable
steady states the system eventually attains.
Bistability in in vitro experiments and model validation.
Evidence of this threshold and the underlying bistability is found
in recent in vitro experiments28. In the latter experiments, cells
were treated with IFN before or at different times post infection
160
120
80
40
0
Q2
Q1
Q3
105 106 107 108
ISG proteins (molecules per cell)
Po
si
tiv
e
-s
tra
n
d 
HC
V 
RN
A
(m
ole
cu
les
 pe
r c
ell
)
Figure 2 | HCV-induced bistability in the IFN signalling network. Model
predictions of concentration-effect curves showing steady state positive-
strand HCV RNA levels for fixed total ISG protein levels (blue line) and total
ISG protein levels for fixed double-stranded HCV RNA levels (red line). Both
curves are drawn with positive-strand HCV RNA levels on the y axis and ISG
protein levels on the x axis. The ISG proteins include the seven ISGs, namely,
IFIT3, IFITM1, IFITM3, PLSCR1, TRIM14, Viperin and RNase L, identified
recently to have anti-HCV activity24 (Supplementary Note 1). The
intersections of the curves mark the three steady states, Q1, Q2 and Q3, of
the network. Parameters employed are listed in Supplementary Tables 1–3.
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Figure 1 | Schematic of the IFN signalling network in the presence of HCV. Following exposure to IFN, signalling via the JAK–STAT pathway triggers
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phosphorylates eIF2a-GDP, which sequesters eIF2B and lowers translation of ISG mRNA. Inset: schematic of the double-negative feedback in the network
owing to the suppression of HCV by ISG proteins and of ISG proteins by HCV.
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and HCV RNA and ISG protein levels were measured 20 h post
IFN treatment28. When treated up to 24 h post infection,
phosphorylated PKR levels were low, ISG protein levels were
high and HCV RNA levels suppressed. When treatedZ48 h post
infection, phosphorylated PKR levels were high, ISG protein
levels low and HCV RNA levels approached that of IFN untreated
cells. Using parameter values obtained independently (Supple-
mentary Note 2, Supplementary Tables 1–3), our model captured
the above observations quantitatively (Fig. 3a). According to our
model, following infection, the HCV RNA level gradually
increases inside cells (Supplementary Fig. 1A); endogenous IFN
production is not expected in the in vitro cell-culture infection
system43. If IFN is added when the HCV RNA level is below the
threshold corresponding to Q2, the system drops to Q3, where
HCV is controlled. In contrast, if IFN is added after the HCV
RNA level crosses the threshold, the system reaches Q1, where
HCV persists. The switch in the response of the system based on
the time of IFN addition is thus a signature of bistability. Indeed,
silencing PKR, which suppresses one of the feedback loops,
eliminated this signature in the experiments and in our model
predictions (Fig. 3b). Further, our model mimicked all the
observations of the latter in vitro study28 (Supplementary Note 3,
Supplementary Figs 1–3), giving us confidence in its ability to
accurately unravel the behaviour of the underlying network.
Diversity of the cellular response to IFN. We found that the
network exhibited bistability over several-fold changes in the
values of several parameters (Supplementary Fig. 4). Global
sensitivity analysis yielded parameters to which the systems-level
properties of the network were sensitive (Supplementary Note 4,
Supplementary Fig. 4). Bistability was lost when parameter values
tilted the competition between HCV and IFN heavily in favour of
either one. For instance, when the repression coefficients for the
control of HCV replication by ISGs were decreased, IFN effec-
tiveness increased and the system admitted the steady state Q3
alone, where HCV is eliminated. When the repression coefficients
were increased, IFN effectiveness decreased and the system
admitted Q1 alone, where HCV thrives (Fig. 4a).
It follows that intrinsic variations across cells, for example, in
ISG expression44,45 or the expression of host protease and other
enzymes that affect HCV replication, would yield three distinct
cellular phenotypes based on the response to a given level of IFN
stimulation, viz., cells that admit Q1 alone, Q3 alone or both Q1
and Q3. Cells that admit Q1 alone would allow HCV persistence
even with IFN stimulation. Cells that admit Q3 alone would clear
HCV following IFN stimulation. Cells that admit both Q1 and Q3
would either allow HCV persistence or clear HCV depending on
the time of IFN addition, as illustrated above. Increasing the level
of IFN stimulation could convert a cell that admits Q1 alone to
one that admits both Q1 and Q3 and further to one that admits Q3
alone. Decreasing the level of IFN stimulation could reverse these
transitions. Bistable systems, however, display hysteretic
behaviour: the level of IFN stimulation required to drive a cell
from Q1 to Q3 would be larger than the level at which the cell
transitions from Q3 to Q1. The former level may lie beyond
experimentally/clinically employed levels of IFN28 (Fig. 4b). Thus,
cells in the state Q1 may allow HCV persistence despite seemingly
high levels of IFN stimulation and are therefore predicted to be
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Figure 3 | Model validation against in vitro data. Normalized positive-strand HCV RNA levels predicted by our model (orange) and measured previously
in in vitro experiments28 (green) at 20 h post IFN treatment (100 IUml 1) following different specified times (hours post infection) with HCV. Error bars
represent standard deviations from triplicates. Lower inset: model predictions of corresponding HCV RNA levels achieved at steady state post IFN
treatment. Upper inset: model predictions of corresponding ISG protein levels at 20 h (orange) and at steady state (blue) post IFN treatment. (a) normal
cells and (b), PKR-silenced cells (60% reduction in PKR mRNA transcription rate). The dashed line marks zero. Normalization was done with the positive-
strand HCV RNA level in cells without IFN treatment. Parameters employed are listed in Supplementary Tables 1–3.
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refractory to IFN. In contrast, cells in the state Q3 clear HCV
infection with much lower levels of IFN stimulation following
exposure to HCV (Fig. 4b). The latter cells are thus sensitive to
IFN. How an HCV-infected individual responds to IFN-based
treatment would thus be determined by the distribution of cells in
the individual across the different IFN response phenotypes.
Viral kinetics and treatment outcome. To predict the ensuing
viral kinetics and treatment outcome, we advanced the basic
model of viral kinetics in vivo14,46–49 (Supplementary Note 5) by
explicitly considering cell subpopulations with the three distinct
IFN response phenotypes (Fig. 5a). We divided target cells into
subpopulations Ti with i¼ 1, 2 and 3 representing cells that admit
Q1 alone, both Q1 and Q3, and Q3 alone, respectively, at the level
of IFN exposure employed in the treatment; because ribavirin
potentiates IFN activity, the subpopulations may be defined based
on the combined activity of PR. Correspondingly, infected cells
are divided into subpopulations I1, I2 and I3. From the above
analysis, it follows that cells T1 remain susceptible to infection
and are refractory to IFN. IFN does not inhibit de novo infection
in this subpopulation. Cells T2 are sensitive to IFN, as IFN
exposure before HCV infection drives these cells to the state Q3
and prevents de novo infections. Cells T3 are similarly protected
from new infections. Cells I1 are again refractory to IFN and
continue viral production. Cells I2 are infected before IFN
exposure and thus attain the state Q1 following IFN exposure and
continue to produce virions. Cells I3 admit Q3 alone and are
cured following exposure to IFN.
The resulting viral kinetics typically follows a biphasic decline
(Fig. 5b). We estimate with our model that the viral load at the
end of the first phase isBV0(1–f3), where V0 is the baseline viral
load and f3 is the pre-treatment frequency of IFN-sensitive cells
(Supplementary Note 6, Supplementary Fig. 5A). The extent of
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Figure 5 | Viral kinetics following IFN treatment. (a) Schematic of viral kinetics incorporating distinct cellular responses to IFN. Top: cells that have poor
IFN control of HCV (left) admit Q1 alone and are refractory to IFN (right). Middle: cells that have intermediate IFN control of HCV and vice versa (left)
admit both Q1 and Q3 and thus continue viral production when infected but are protected from new infections by IFN (right). Bottom: cells that have strong
IFN control of HCV (left) admit Q3 alone and are sensitive to IFN (right). Target cells in the three subpopulations, Ti, where i¼ 1, 2 and 3, are produced at
the rates si, proliferate with the rate constant rT, die with the rate constant dT and are lost owing to de novo infection with the rate constant b. The
corresponding infected cells Ii proliferate with the rate constant rI and die with the rate constant d. Free virions are produced by infected cells with the rate
constant p and are cleared with the rate constant c. The de novo infection rate and virion production rate were assumed to be blocked with efficacies Zi and
ei in the respective subpopulations owing to PR treatment. (b) Model predictions of different viral response patterns following IFN treatment for different
distributions of cells in the three IFN response phenotypes: f1¼ 1, f2¼0, and f3¼0 (green top); f1¼0.35, f2¼0.35, and f3¼0.3 (green bottom);
f1¼0.015, f2¼0.185, and f3¼0.8 (red); and f1¼0, f2¼0.2, and f3¼0.8 (blue). (c) Steady state viral levels following IFN treatment as a function of
f1 when f2¼f3 (solid line) and f2¼0.5f3 (dashed line) (the two curves overlap) and (Inset) long-term virological response corresponding to the
predictions in b. Parameters: V0¼ 7 106 IUml 1, b¼ 3 10 7ml per virions per day. Other parameter values employed are listed in Supplementary
Table 4.
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the first phase decline is thus determined by the fraction of cells
cured by IFN. The second phase slope depends on the dynamics
of the infected cells. Whereas cells I2 and I3 decline at the death
rate d—de novo infection is blocked by IFN in these subpopula-
tions and infected cells are expected not to proliferate
significantly48 (Supplementary Table 4)—the loss of cells I1 is
compensated at least in part by the de novo infection of cells T1,
refractory to IFN (Supplementary Note 5, Supplementary
Fig. 5B). The early second phase slope estimated using our
model isBd(1–f1). The second phase slope thus decreases as the
pre-treatment frequency of IFN-refractory cells, f1, increases
(Supplementary Note 6, Supplementary Fig. 5C). By varying the
frequencies f1, f2 and f3, our model reproduced all the patterns
of viral kinetics observed in patients (Fig. 5b).
The second phase slope in our model depends on f1. Indeed,
we find that when f1 is below a critical value, f
c
1, viral clearance
is achieved (Fig. 5c). This critical value does not depend on f2
and f3 because following treatment, cells T2 and T3 do not
acquire new infections and cells I2 and I3 are eventually lost
owing to cell death even when IFN fails to cure them. IFN-
refractory cells, T1, remain susceptible to new infections even
during treatment and thus determine treatment outcome. When
their number is sufficiently small, viral production from infected
cells is inadequate to replenish the loss of infected cells owing to
cell death (akin to the basic reproductive number being below
unity50), resulting in the eventual clearance of infection. Thus,
the success of IFN treatment depends primarily on the size
of the IFN-refractory subpopulation. The larger the latter sub-
population, the smaller the second phase slope, thus presenting
an explanation of the strong correlation observed between the
second phase slope and treatment response46,51,52.
Comparison with patient data. We next applied our model to
analyze data of viral kinetics obtained previously from patients
under IFN monotherapy46. Our model provided excellent fits to
the data (Fig. 6a, Supplementary Fig. 6, Supplementary Tables 5
and 6). In agreement with our prediction above, we found
from the fits that cf1, an upper bound on f1 obtained by letting
f2¼ 0, increased from 0.01 for a typical rapid responder, to 0.11
for a slow partial responder and 0.37 for a null responder.
Similarly, patients with known favourable haplotypes based
on SNPs in the IFN-l locus had significantly lower cf1 on an
average than patients with unfavourable haplotypes
(Supplementary Fig. 6, Supplementary Table 6). Finally,
we estimated cf1 for a large set of patients under IFN
monotherapy51,53 and found it to be negatively correlated with
the second phase slope (Fig. 6b), reiterating the dependence of the
second phase slope and hence treatment outcome on the
frequency of IFN-refractory cells.
Pre- and post-treatment ISG expression and response to IFN.
We next examined how treatment response correlated with pre-
and post-treatment ISG expression. The pre-treatment frequency
of cells refractory to IFN would depend on the level of endo-
genous IFN production following infection as well as the strength
of the effector function of ISGs, or, more generally, the effector
function of the IFN network. IFN production stimulates the IFN
network, whose effector function determines the propensity to
clear HCV. Four possibilities thus arise (Fig. 7).
When endogenous IFN production is low (for example, owing
to HCV-mediated cleavage of mitochondrial antiviral signaling
protein (MAVS)43,54) and IFN effector function potent, infection
is established because of inadequate stimulation of the IFN
network. ISG levels are predicted to be low in such individuals
before treatment (Fig. 7a). Exogenous IFN addition during
treatment stimulates the IFN network, which increases ISG
expression and, given potent IFN effector function, clears
infection. Cells in such individuals predominantly admit Q3 at
the level of IFN exposure during treatment. Such individuals are
predicted to be rapid responders to IFN treatment (Fig. 7c).
When endogenous IFN production is high but IFN effector
function compromised, infection is established despite stimula-
tion of the IFN network. Here ISG levels are high before
treatment (Fig. 7b), but HCV continues to thrive because of poor
effector function. Cells in such individuals predominantly admit
Q1 and addition of exogenous IFN contributes little to the control
of infection. Such individuals are predicted to be null responders
to treatment (Fig. 7c).
When both endogenous IFN production and ISG effectiveness
are low, addition of IFN may increase ISG levels but not
necessarily clear HCV given the inadequate effector function.
Such individuals appear as partial responders. The fraction of
IFN-refractory cells is smaller in such individuals than in null
responders, but treatment would fail as long as the fraction is
larger than the critical value mentioned above. When both
endogenous IFN production and ISG effectiveness are high,
infection is likely to be spontaneously cleared; spontaneous
clearance has been observed to additionally require strong
cytotoxic T-cell responses22, which our study did not consider.
We note that IFN effector function is compromised at steps
downstream of the step(s) in the IFN signalling network at which
HCV interferes. For instance, HCV interfered above at the level of
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the estimation of both f1 and f2 uniquely. We therefore assumed f2¼0
and estimated bf1 as the corresponding upper bound on f1. We thus let b,
V0 and bf1 be adjustable parameters. The resulting estimates of bf1, which
were robust to variations in the fixed parameters (Supplementary Fig. 11),
are mentioned above. The best-fit parameter estimates and measures of
goodness of fit are listed in Supplementary Table 5. Other parameter values
employed are listed in Supplementary Table 4. (b) Pre-treatment frequency
of IFN-refractory cells and the slope of the second phase decline estimated
from data in two reports on patients under IFN monotherapy (closed
circles: ref. 51; open circles: ref. 53) are strongly correlated (Pearson’s
correlation coefficient, R¼ 0.44, Po0.001). Using the standard model of
viral dynamics, the efficacy of IFN, e, and the death rate of infected cells, d,
were estimated from previously published data of viral kinetics for the
patients51,53. The second phase slope is the product de according to the
standard model. Further, e in the standard model corresponds to f3 in our
model, which yielded bf1 ¼ 1 e.
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ISG translation, so that poor effector function arose from low
levels of ISG proteins despite high-ISG mRNA levels. In this case,
both uninfected and infected cells would display high-pre-
treatment ISG mRNA expression in nonresponders. If, instead,
HCV were to predominantly inhibit the JAK–STAT pathway, low
effector function would arise from low ISG mRNA expression.
High-pre-treatment ISG expression in nonresponders would then
be restricted to uninfected cells via paracrine signalling.
Synergy between DAAs and IFN. Finally, we examined the
origin of the synergy between DAAs and IFN. DAAs such as
HCV protease and polymerase inhibitors lower the HCV repli-
cation rate and would therefore weaken the control of HCV on
the IFN network. To characterize the impact of such a DAA, we
identified the steady states of the network at different (dose-
dependent) DAA efficacies (Fig. 8a). At low DAA efficacies, the
system again exhibits the bistable behaviour observed earlier. As
the efficacy increases, the HCV RNA level corresponding to Q1
declines and that corresponding to Q2 increases. Interestingly,
beyond a critical efficacy, the HCV-high state is rendered
unsustainable and the system jumps to Q3 where HCV is cleared.
The DAA thus transforms a bistable cell into a cell that admits Q3
alone. Similarly, a cell that admits Q1 alone could be transformed
into one that admits both Q1 and Q3 (Fig. 8b). At the cell
population level, this effect of the DAA would manifest as an
increase in the fraction of IFN-sensitive cells, f3, at the expense of
IFN-refractory cells, f1, and thus result in improved treatment
response.
Discussion
A hallmark of HCV infection has been its persistence in many
individuals despite strong ISG expression in the liver and high
doses of IFN and ribavirin8–10. What underlies this persistence
has remained poorly understood. In the present study, we provide
a new conceptual basis for understanding HCV persistence and
response to IFN-based treatment.
Negative regulators of the IFN system, such as SOCS and
USP18, as well as the recently identified IFN-associated
immunosuppression have been suggested to contribute to viral
persistence despite IFN stimulation6,20,21. While these
mechanisms are undoubtedly important, they remain partial
determinants of HCV persistence and treatment response because
they do not explain when pre-treatment ISG expression would be
high. Further, a direct role of HCV in suppressing IFN effector
function may be important in determining treatment response
because DAAs that suppress HCV replication can induce SVRs in
previous null responders to PR. Our study predicts that these
additional mechanisms, potentially central to HCV persistence
and treatment response, may arise from the systems-level
properties of the IFN signalling network modulated by HCV.
Our model of the IFN signalling network predicts that HCV
induces bistability in the network. IFN signalling is designed to
clear viral infections. HCV interferes with IFN signalling and
introduces an alternative steady state where HCV persists. To our
knowledge, this is the first instance identified where a virus
induces bistability in an innate immune signalling network to
achieve persistence. A consequence is that IFN effector function
can be compromised despite high-IFN production, allowing viral
persistence in the presence of high-ISG expression. Addition of
exogenous IFN yields no additional antiviral effect. When more
than a critical fraction of cells in an individual is refractory to
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Figure 8 | Influence of DAA on IFN responsiveness. (a) Concentration-
effect curves showing steady state positive-strand HCV RNA levels for
fixed ISG protein levels (blue lines) and ISG protein levels for fixed double-
stranded HCV RNA levels (red lines) in the presence of a DAA at different
efficacies (eDAA). (b) Steady states of the network as a function of DAA
efficacy. In a, o¼ 1, g¼ 1. In b, o¼ 10, g¼0.1. o and g represent the
fold changes in the repression coefficients of all ISGs and the eIF2B
production rate constant, respectively, relative to their baseline values in
Supplementary Table 3. Other parameters are listed in Supplementary
Tables 1–3.
108
Pre-treatment
Post-treatment
Pre-treatment
Post-treatment106
104
102
100
0
HCV
RNA
IFITM3
mRNA
Null responders
1 >> 1
c
1 > 1
c 1 < 1
c
Partial responders
Δ /SG, ΔV–moderate
Δ /SG, ΔV–low
Δ /SG, ΔV–high
Rapid responders
Likely spontaneous
clearers
IFITM3
protein
HCV
RNA
IFITM3
mRNA
IFITM3
protein
M
ol
ec
ul
es
 p
er
 c
el
l
108
106
104
102
100
0
M
ol
ec
ul
es
 p
er
 c
el
l
En
do
ge
no
us
 IF
N 
pr
od
uc
tio
n
Lo
w
Low
H
ig
h
High
Strength of IFN effector function
Figure 7 | Pre- and post-treatment ISG expression and treatment
response. Pre- and post-treatment steady state positive-strand HCV RNA,
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effector function (o¼0.5, g¼ 1), representative of responders, and (b), an
IFN-refractory cell with high-endogenous IFN level (IFNendo¼ 100Uml 1)
but poor effector function (o¼ 20, g¼0.1), representative of
nonresponders. The dashed line marks zero. IFITM3 is shown as a
representative ISG; other ISGs behave similarly. (c) Schematic of expected
responses to IFN-based treatment in patients with different endogenous
IFN production levels and potencies of IFN effector function. f1 is the pre-
treatment frequency of IFN-refractory cells, fc1 is the critical pre-treatment
frequency of IFN-refractory cells for successful treatment response, DV is
the fold-decline in viral load and DISG is the fold increase in ISG mRNA
levels relative to their respective pre-treatment levels. o and g represent the
fold changes in the repression coefficients of all ISGs and the eIF2B
production rate constant, respectively, relative to their baseline values in
Supplementary Table 3. Parameters: IFNexo¼ 100Uml 1. Other parameters
are listed in Supplementary Tables 1–3.
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IFN, treatment would fail. DAAs improve treatment response by
suppressing HCV replication, which compromises the ability of
HCV to induce bistability in the network, thereby lowering the
fraction of cells refractory to IFN.
The IFN signalling network comprises a large number of
molecular components that interact via multiple feedback loops5.
HCV interferes with the network at several levels6,22. A complex
combination of molecular players as well as parameter values
determining the strengths of their interactions may thus underlie
the phenotypic response of an HCV-infected cell to IFN.
Currently, the limited knowledge of cell-to-cell and inter-
patient variations in parameter values (for example, see ref. 55)
precludes a priori estimation of the prevalence of IFN-refractory
cells in patients and hence the establishment of a quantitative link
between network properties and viral kinetics. Nonetheless, we
found that HCV-induced bistability is a robust emergent property
of the network: in addition to the translational block induced by
HCV considered above, with which current in vivo data29 seems
consistent, we examined other known modes of HCV interference
of the IFN network and also negative regulation of IFN
stimulation by ISG proteins. We found bistability in all cases
(Supplementary Notes 7 and 8, Supplementary Figs 7 and 8).
Bistability was also maintained under parameter regimes that
mimicked the dynamic oscillations in HCV-induced translational
inhibition observed recently56,57 (Supplementary Note 9,
Supplementary Fig. 9). Further, our prediction that the pre-
treatment prevalence of IFN-refractory cells beyond a critical
fraction leads to treatment failure is independent of the origin of
the bistability.
Previous models of viral kinetics have estimated the effective-
ness of PR by comparisons of model predictions with viral load
decline in patients14,46–49,58. Our model reproduced all the
patterns of viral kinetics observed in patients by varying the
fractions of cells refractory and sensitive to IFN. Alternative
interpretations thus emerge of the effectiveness estimated by
previous models. The extent of first phase decline, which is taken
as a measure of IFN effectiveness in lowering viral production, is
in our model a measure of the pre-treatment fraction of infected
cells that are subsequently cured by PR. The slope of the second
phase, which is taken as a combination of PR effectiveness and
the loss rate of infected cells, is in our model a combination of the
loss rate of infected cells and the fraction of cells refractory to PR.
Larger the latter fraction, smaller the slope, and hence poorer the
treatment response. The critical effectiveness of PR predicted by
previous models47 for successful treatment translates to the level
of PR activity necessary to render the fraction of cells refractory to
PR below the critical value identified by our model. Our model
thus presents an alternative yet equally consistent description of
viral kinetics and one that is rooted in the properties of the IFN
network.
The synergy between DAAs and IFN predicted by our model
can be compromised by the emergence of resistance to DAAs,
which we did not consider. Recent studies have reported the
dependence of viral kinetics on SNPs even in IFN-free treatment
regimens59,60 and recent trials with some two-DAA combinations
without PR have been stunningly successful with 490% SVR
in previous null responders to PR61. We speculate that this
success may arise from a combination of three modes of DAA
action. First, the DAAs may directly suppress HCV replication.
Second, they may render cells monostable and facilitate HCV
clearance. Third, the resulting lower HCV levels may lead to
lower IFN stimulation, which in the absence of exogenous
IFN may undo the immunosuppression caused by persistent
IFN signalling and effect a cure. Identifying which of these
mechanisms predominates in vivo awaits new investigations and
may inform future strategies of intervention.
Methods
Mathematical model of the IFN signalling network. We modelled the network
(Fig. 1) based on mass action and Michaelis–Menten kinetics (Supplementary Note
1). The parameters involved (Supplementary Tables 1–3) were either obtained from
the literature or estimated from analysis of independent experiments of intracellular
HCV RNA kinetics (Supplementary Figs 3 and 10), ISG expression following
stimulation with IFN, and suppression of HCV RNA by over-expression of ISGs
(Supplementary Note 2). The fit of this model to the highly infectious HCV JFH-m4
strain can be found in Supplementary Fig. 10 and Supplementary Note 2.
Mathematical model of viral kinetics. We modified the standard model of HCV
viral kinetics to incorporate subpopulations of cells with distinct phenotypic
responses to IFN (Fig. 4, Supplementary Note 5). We obtained analytical
approximations to the resulting first and early second phase slopes (Supplementary
Note 6). The parameter values employed were obtained from the literature or
estimated from fits to patient data (Supplementary Tables 4–6).
Solution of model equations and data analysis. We solved the model of the IFN
signalling network and the model of viral kinetics using the Rosenbrock algorithm
in Berkeley-Madonna version 8.3.18 and the ode15s routine in MATLAB. We fit
the model predictions to the data using the nonlinear regression tool NLINFIT in
MATLAB and estimated 95% confidence intervals using the tool NLPARCI in
MATLAB. We assessed the goodness of fits using R2 and the Student’s t-test on
residuals. All data digitization was done using Engauge digitizer. The computer
programs employed are available upon request.
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